Full Press Release Details
Key Stakeholders Support Cryo-Cell International Leadership in Proxy Contest
(July 5, 2012) Individuals who are in the best position to observe and evaluate the performance of the current Cryo-Cell International [OTCQB symbol: CCEL] Board and executive management are strongly supporting them as they face a bid for
control of the company by a former Board member. The group assumed leadership in August 2011.
About Cryo-Cell International, Inc.
Cryo-Cell International, Inc. was founded in 1989. In 1992, it became the first private cord blood bank in the world to separate and store stem cells. Today, nearly 500,000 parents worldwide trust
Cryo-Cell to store their newborns stem cells. Cryo-Cell s mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine.
Cryo-Cell operates in a facility that is compliant with Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP). It is ISO 9001:2008 certified
and accredited by the American Association of Blood Banks. Cryo-Cell is a publicly traded company, OTC:QB Markets Group Symbol: CCEL.
Forward-Looking Statement
wherein the terms believes , intends , projects , anticipates , expects , and similar expressions as used are intended to reflect forward-looking statements of the company. The
information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside
the control of the company. These uncertainties and other factors include the success of the company s global expansion initiatives and product diversification, the company s actual future ownership stake in future therapies emerging from
its collaborative research partnerships, the success related to its IP portfolio, the company s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on
the company s business, the company s ability to minimize future costs to the company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the
company s menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the
company and those risks and uncertainties contained in risk factors described in documents the company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q and any Current Reports on Form 8-K filed by the company. The company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
Cryo-Cell International, Inc.